Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab versus mepolizumab in relapsing or refractory EGPA
NL-OMON60614Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in eosinophilic granulomatosis with polyangiitis (EGPA) comparing Depemokimab arm with Mepolizumab arm (2 arms). Primary endpoint: Remission at Weeks 36 and 52. Started Mar 2023; status: completed.
02
Drugs
depemokimabmepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on NL-OMON60614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60614.